Shares of NantHealth Inc (NASDAQ:NH) have received an average rating of “Buy” from the six research firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $4.58.
A number of equities research analysts have commented on NH shares. BidaskClub raised shares of NantHealth from a “hold” rating to a “buy” rating in a report on Friday, July 6th. ValuEngine raised shares of NantHealth from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. Finally, Canaccord Genuity reissued a “hold” rating on shares of NantHealth in a report on Tuesday, July 3rd.
NantHealth opened at $2.83 on Friday, MarketBeat reports. NantHealth has a 12-month low of $2.60 and a 12-month high of $5.26. The firm has a market cap of $306.77 million, a P/E ratio of -2.52 and a beta of 0.23. The company has a current ratio of 1.90, a quick ratio of 1.88 and a debt-to-equity ratio of 1.15.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Deutsche Bank AG increased its holdings in NantHealth by 117.4% during the fourth quarter. Deutsche Bank AG now owns 45,610 shares of the company’s stock worth $137,000 after buying an additional 24,635 shares during the last quarter. Millennium Management LLC acquired a new position in NantHealth during the fourth quarter worth $344,000. BlackRock Inc. increased its holdings in NantHealth by 9.0% during the second quarter. BlackRock Inc. now owns 2,337,249 shares of the company’s stock worth $7,735,000 after buying an additional 193,491 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in NantHealth by 41.7% during the second quarter. Dimensional Fund Advisors LP now owns 120,348 shares of the company’s stock worth $398,000 after buying an additional 35,445 shares during the last quarter. Institutional investors own 5.62% of the company’s stock.
NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.
Recommended Story: Average Daily Trade Volume – ADTV
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.